Acute myeloid leukaemia Patients     

FOI REFERENCE: 24049

FOI TITLE: Acute myeloid leukaemia Patients  

FOI DATE: 17^th April 2024  

1. Do you treat patients with acute myeloid leukemia (AML) in your Trust? Yes

2. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period October 223 to March 2024?

Azacitidine monotherapy – * patients

Low dose cytarabine (LoDAC) monotherapy – * patients

Venetoclax + azacitidine – 31 patients

Venetoclax + LoDAC – 0 patients

Ivosidenib – 0 patients

Intensive chemotherapy-based regimen

Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)

Best supportive care

Other

Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants

Note: this should only include patients with AML who have started first-line treatment during the 6-month window

Treatment option	Number of newly diagnosed patients with AML starting first line treatment during the 6-month period October 2023 to March 2024
Azacitidine monotherapy	*
(LoDAC) monotherapy	0
Venetoclax + azacitidine	27
Venetoclax + LoDAC	0
Ivosidenib	0

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018